Ken Griffin Nuvation Bio Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$2.3 - $3.83 $14,949 - $24,895	-6,500 Reduced 67.01%	3,200 $7,000
Q2 2024 Aug 14, 2024	SELL	$2.58 - $3.69 $79,722 - $114,021	-30,900 Reduced 76.11%	9,700 $28,000
Q1 2024 May 15, 2024	BUY	$1.46 - $3.97 $52,268 - $142,126	35,800 Added 745.83%	40,600 $147,000
Q4 2023 Feb 14, 2024	SELL	$0.96 - $1.53 $19,104 - $30,447	-19,900 Reduced 80.57%	4,800 $7,000
Q3 2023 Nov 14, 2023	BUY	$1.26 - $2.1 $24,822 - $41,370	19,700 Added 394.0%	24,700 $33,000
Q2 2023 Aug 14, 2023	BUY	$1.56 - $1.84 $7,644 - $9,016	4,900 Added 4900.0%	5,000 $9,000
Q1 2023 May 15, 2023	SELL	$1.6 - $2.48 $1,280 - $1,984	-800 Reduced 88.89%	100 $0
Q4 2022 Feb 14, 2023	BUY	$1.68 - $2.5 $1,512 - $2,250	900 New	900 $1,000

159

157M

3.2K

98.7K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $630M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.